Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: Immortal and neglected time bias

American Journal of Epidemiology

Volumn 170, Issue 3, 2009, Pages 280-285

  Heerdink, Eibert R ^a   Gardarsdottir, Helga ^b   Egberts, Toine C ^b   Stolker, Joost J ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

Antidepressant agents; Bias (epidemiology); Depressive disorder; Pharmacoepidemiology; Recurrence

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

DISEASE TREATMENT; DRUG USER; EPIDEMIOLOGY; HEALTH IMPACT; HEALTH RISK; HEALTH SERVICES; MENTAL HEALTH; PSYCHOLOGY;

ADULT; AGED; ARTICLE; DEPRESSION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; IMMORTAL TIME BIAS; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NEGLECTED TIME BIAS; NETHERLANDS; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; RELAPSE; RISK ASSESSMENT; STATISTICAL ANALYSIS; SYSTEMATIC ERROR; TREATMENT DURATION;

ANTIDEPRESSIVE AGENTS; BIAS (EPIDEMIOLOGY); COHORT STUDIES; CONFIDENCE INTERVALS; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PHARMACOEPIDEMIOLOGY; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

BENELUX; EURASIA; EUROPE; NETHERLANDS; WESTERN EUROPE;

EID: 67749147236     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp142     Document Type: Article

References (29)

1. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002; 159(3):469-473.
2. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998; 55(12):1128-1132.
3. Claxton AJ, Li Z, McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry. 2000;177:163-168.
4. Sood N, Treglia M, Obenchain RL, et al. Determinants of antidepressant treatment outcome. Am J Manag Care. 2000; 6(12):1327-1336.
5. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007;164(8):1189-1197.
6. Schneider F, Härter M, Brand S, et al. Adherence to guidelines for treatment of depression in in-patients. Br J Psychiatry. 2005;187:462-469.
7. Goering P. Collaborative care speeds recovery from depression. Evid Based Ment Health. 2003;6(4):116.
8. Pampallona S, Bollini P, Tibaldi G, et al. Patient adherence in the treatment of depression. Br J Psychiatry. 2002;180:104-109.
9. Tai-Seale M, Croghan TW, Obenchain R. Determinants of antidepressant treatment compliance: implications for policy. Med Care Res Rev. 2000;57(4):491-512.
10. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry. 2006;188: 346-353.
11. Donoghue J, Hylan TR. Antidepressant use in clinical practice: efficacy v. effectiveness. Br J Psychiatry. 2001;42(suppl): S9-S17.
12. Bambauer KZ, Adams AS, Zhang F, et al. Physician alerts to increase antidepressant adherence: fax or fiction? Arch Intern Med. 2006;166(5):498-504.
13. Edlund MJ, Wang PS, Berglund PA, et al. Dropping out of mental health treatment: patterns and predictors among epi-demiological survey respondents in the United States and Ontario. Am J Psychiatry. 2002;159(5):845-851.
14. Aikens JE, Nease DE Jr, Nau DP, et al. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med. 2005;3(1): 23-30.
15. Keller MB, Hirschfeld RM, Demyttenaere K, et al. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol. 2002;17(6):265-271.
16. Mann JJ. The medical management of depression. N Engl J Med. 2005;353(17):1819-1834.
17. U.S. Behavioral Health Plan, California. 2006 Best Practice Treatment Guideline: Supplemental and Measurable Guideline for the Treatment of Major Depressive Disorder. (http:// www.ubhonline.com/html/guidelines/ preferredPracticeGuide-lines/pdf/supplmajrdepr.pdf). (Accessed November 20, 2007).
18. Institute for Clinical Systems Improvement. Health Care Guideline: Major Depression in Adults in Primary Care. 11th ed. May 2008. (http://www.icsi.org/depression-5/ depression--major--in-adults-in-primary-care- 3.html).
19. Westert GP, Schellevis FG, de Bakker DH, et al. Monitoring health inequalities through general practice: the Second Dutch National Survey of General Practice. Eur J Public Health. 2005;15(1):59-65.
20. Lamberts H, Wood M. International Classification of Primary Care. Oxford, United Kingdom: Oxford University Press; 1987.
21. Tinke J, Griens A. Facts and Figures 2001. The Hague, The Netherlands: Foundation for Pharmaceutical Statistics; 2001.
22. Florentinus SR, Souverein PC, Griens FA, et al. Linking community pharmacy dispensing data to prescribing data of general practitioners [electronic article]. BMC Med Inform Decis Mak. 2006;6:18.
23. Gardarsdottir H, Heerdink ER, van Dijk L, et al. Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord. 2007;98(1-2):109-115.
24. Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998.
25. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492-499.
26. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(8):842-846.
27. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1): 49-53.
28. Ustün TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004; 184:386-392.
29. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration [electronic article]. PLoS Med. 2008;5(2):e45.